CYTK Long — CYTK breaks to 52w highs on aficamten trial success

Setup: CYTK exploded 16%+ today on massive volume (3.8M+ shares on the catalyst bar alone, versus typical sub-300K) after aficamten met primary endpoints — a hard binary event with clean follow-through. On the 4h, price broke decisively above the prior Feb swing high (~70) and is now in clear price discovery at 52-week highs. The 1h shows the initial spike bar followed by a high-volume continuation, with price consolidating in the upper range of today's move rather than giving back gains aggressively — constructive action post-catalyst.

Flow: Bullish options activity cited in the symbol context confirms the market is pricing in further upside, not fading the move. Analyst consensus sits at Strong Buy with a mean target of $93, providing fundamental cover for the breakout thesis. Insider selling is noted but is heavy and chronic at biotech names (compensation-driven), not a directional signal here. The broader tape is firmly bullish (A/D 1.91), providing a favorable macro backdrop.

Plan: Stop is placed below the intraday low of the catalyst bar (~73.07), which represents the first structural invalidation level — a close back below that level would signal the breakout is failing and sellers are absorbing the supply. Target is the analyst mean of $93 area, with an intermediate reference near the 80 highs tested today. The thesis is invalid if price reclaims the pre-catalyst consolidation zone (sub-65) on closing basis.

📍 Entry: 76.50
🛑 Stop: 73.00
🎯 Target: 85.00
⚖️ R:R: 2.43